Shimada Yukinobu, Kitano Hiroyuki, Miyamoto Shunsuke, Kobatake Kohei, Goto Keisuke, Goriki Akihiro, Hieda Keisuke, Hirokawa Yutaka, Hinata Nobuyuki
Department of Urology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan.
Department of Radiation Therapy Hiroshima Heiwa Clinic Hiroshima Japan.
IJU Case Rep. 2025 Jul 15;8(5):441-444. doi: 10.1002/iju5.70052. eCollection 2025 Sep.
Despite the recent increase in applicable chemotherapy regimens for renal pelvic and ureteral cancer, patients with metastases still exhibit a poor prognosis. Here, we report a patient with renal pelvic cancer for whom long-term survival was achieved using chemoradiotherapy.
A 62-year-old woman diagnosed with renal pelvic cancer showed indications of a right renal pelvic tumor with para-aortic and iliac lymph node metastasis on computed tomography. Radiotherapy doses of 55 and 66 Gy were administered to the primary lesion, para-aortic lymph node, and right iliac lymph nodes after chemotherapy with gemcitabine, cisplatin, and docetaxel. Five years after treatment, no recurrence was observed.
Chemoradiotherapy is a potential therapeutic option for patients with renal pelvic carcinoma in whom surgical intervention is challenging owing to complications or older age.
尽管最近适用于肾盂和输尿管癌的化疗方案有所增加,但发生转移的患者预后仍然较差。在此,我们报告一例通过放化疗实现长期生存的肾盂癌患者。
一名62岁被诊断为肾盂癌的女性在计算机断层扫描中显示右肾盂肿瘤并有主动脉旁和髂淋巴结转移迹象。在用吉西他滨、顺铂和多西他赛化疗后,对原发灶、主动脉旁淋巴结和右髂淋巴结给予55和66 Gy的放射治疗剂量。治疗五年后未观察到复发。
对于因并发症或年龄较大而手术干预具有挑战性的肾盂癌患者,放化疗是一种潜在的治疗选择。